DGAP-News: CEVEC Pharmaceuticals GmbH / Key word(s): Alliance
CEVEC and CellGenix sign collaboration and license agreement for
CEVEC's proprietary CAP(R)Go technology
07.10.2015 / 08:30
---------------------------------------------------------------------
CEVEC and CellGenix sign collaboration and license agreement for CEVEC's
proprietary CAP(R)Go technology
- CEVEC provides expertise and grants license for the production of
selected growth and differentiation factors based on CAP(R)Go
technology
- CEVEC further expands CAP(R)Go applications into the field of GMP-grade
ex vivo cell culture products for cell therapies
- CellGenix provides expertise to develop and manufacture
CAP(R)Go-derived high-quality proteins for clinical cell culture needs
- CellGenix complements its protein production platform with human
expression technology
Cologne and Freiburg, Germany, October 7th, 2015 - CEVEC Pharmaceuticals
GmbH (CEVEC), the expert in the production of tailor-made recombinant
glycoproteins and gene therapy vectors, and CellGenix GmbH, a leading
manufacturer of premium-grade reagents for clinical cell culture needs,
today announced a collaboration and license agreement for the development
and GMP production of selected cytokines for ex vivo cell culture therapy
applications using CEVEC's proprietary CAP(R)Go technology. Financial
details of this agreement were not disclosed.
Under the terms of the agreement, CEVEC offers its expertise regarding the
development of selected CAP(R)Go cell lines as well as its competence for
the expression of a variety of difficult to produce recombinant cytokines.
In addition the company will grant CellGenix a license for the production
and commercialization of CAP(R)Go-derived growth and differentiation
factors.
CellGenix will provide its long-standing expertise in development of
high-quality recombinant ex vivo reagents. In addition the company will use
its in-house GMP manufacturing capabilities, established QA (Quality
Assurance) system as well as its expert regulatory know-how to ensure
compliance of CAP(R)Go-derived products with the complex regulatory
landscape for cell-based therapies. The products will be marketed by
CellGenix and expand the existing portfolio of GMP-grade cell culture
systems to develop preclinical and clinical cell therapies.
"This agreement with CellGenix is a next step with respect to the further
development of our technology in new application areas," commented Frank
Ubags, Chief Executive Officer of CEVEC Pharmaceuticals GmbH. "We
additionally position our platform as the technology of choice to express
certain cytokines in the growing field of ex vivo cell culture therapies.
This is an additional endorsement of our unique human expression system."
"Through CEVEC's CAP(R)Go technology, CellGenix has access to new cytokines
and other proteins which require human post-translational modification,
like glycosylation, and which are therefore not accessible by bacterial
expression," says Prof. Dr. Felicia Rosenthal, Chief Executive Officer of
CellGenix GmbH. "The traceability to the completely characterized and
documented parental CAP(R) Master Cell Bank (MCB) allows to maintain
CellGenix' high safety standards also for future CAP(R)Go-derived,
xeno-free products."
About CellGenix:
CellGenix is a leading manufacturer of premium-grade reagents for clinical
cell culture needs. The company has more than 20 years in-house expertise
in GMP manufacturing and development of products in the field of cell
therapy, gene therapy and regenerative medicine. As trusted supplier
CellGenix offers a comprehensive product portfolio, like preclinical and
GMP-grade cytokines and serum-free media for cell and gene therapy
applications. The products combine a maximum of quality and safety with
excellent performance due to the state-of-the-art production, stringent
in-house quality assurance and comprehensive documentation packages. All
these factors help to simplify qualification and validation for
manufacturing and market authorization and ensure the seamless transition
from research to commercialization.
About CEVEC:
Privately held CEVEC, based in Cologne, Germany, is an expert for the
production of tailor-made recombinant glyco-proteins and gene therapy
vectors. The Company's core technologies, CAP(R)Go and CAP(R)GT are based
on a unique human cellular expression system.
The CAP(R)Go expression platform comprises a portfolio of glyco-optimized
human suspension cell lines for tailor-made glycosylation of recombinant
proteins. The cells are highly efficient for the production of a broad
range of difficult to express glyco-proteins and provide authentic human
post-translational modifications. CAP(R)Go has proven to enhance the
activity, stability and serum half-life of several candidate proteins.
The CAP(R)GT expression platform provides a fully scalable, regulatory
endorsed production system for gene therapy vectors. CAP(R)GT cells grow to
high cell densities and show a broad viral propagation spectrum including
lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV).
Furthermore, CAP(R)GT enables easier scale-up and reduced production costs
when compared to adherent cell culture systems.
Research collaborations with international pharmaceutical and biotechnology
partners followed by licensing agreements for the technology form one
revenue base for CEVEC. In addition, the Company provides contract
manufacturing for the GMP production in CAP(R)Go and CAP(R)GT cells.
Contact:
<pre>
CEVEC Pharmaceuticals GmbH CellGenix GmbH
Frank Ubags Felicia Rosenthal
Chief Executive Officer Chief Executive Officer
T.:+49 221 46020800 T.:+49 761 88889100
E.: ubags@cevec.com E.: rosenthal@cellgenix.com
www.cevec.com www.cellgenix.com
</pre>
<pre>
MC Services AG
Anne Hennecke
Public Relations
T.: +49 211 52925222
E.: anne.hennecke@mc-services.eu
</pre>
---------------------------------------------------------------------
07.10.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
398545 07.10.2015
DGAP-News: CEVEC and CellGenix sign collaboration and license agreement for CEVEC's proprietary CAP(R)Go technology
| Source: EQS Group AG